Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | TDO2 | P48775 | 3/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 8/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA6 | P23280 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 4/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12689573 | 0.92 | IDO1 (0.46) | IDO1TDO2APAF1 | |
| SCHEMBL9103291 | 0.77 | IDO1 (0.54) | IDO1TDO2APAF1 | |
| SCHEMBL9103281 | 0.77 | IDO1 (0.54) | IDO1TDO2APAF1 | |
| SCHEMBL10938753 | 0.72 | TSHR (0.58) | CA12CA9CA2CA1CA4 | |
| SCHEMBL10938748 | 0.72 | TSHR (0.58) | CA12CA9CA2CA1CA4 | |
| SCHEMBL19788610 | 0.71 | CA12 (0.44) | CA12CA9CA2CA1CA4 | |
| SCHEMBL12325804 | 0.65 | APAF1 (0.73) | IDO1TDO2APAF1MAPT | |
| SCHEMBL13342994 | 0.63 | CYP3A4 (0.55) | CA12CA9CA2CA1CYP3A4 | |
| SCHEMBL13163813 | 0.63 | CYP2D6 (0.57) | CA12CA9CA2CA1CA4 | |
| SCHEMBL19861393 | 0.63 | CA12 (0.59) | CA12CA9CA2CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | IDO1 20/4885TDO2 66/4885APAF1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.